

Sharon Ruth Lewin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2552916/publications.pdf>

Version: 2024-02-01

339
papers

24,095
citations

10956

71
h-index

9839

141
g-index

346
all docs

346
docs citations

346
times ranked

24712
citing authors

#	ARTICLE	IF	CITATIONS
1	The end of AIDS: HIV infection as a chronic disease. <i>Lancet, The</i> , 2013, 382, 1525-1533.	6.3	1,428
2	Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virusâ€“infected Macaques. <i>Journal of Experimental Medicine</i> , 1999, 189, 991-998.	4.2	1,311
3	Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 780-790.	1.9	957
4	Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. <i>Nature Medicine</i> , 2020, 26, 453-455.	15.2	917
5	Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 1999, 340, 1605-1613.	13.9	782
6	HIV infection: epidemiology, pathogenesis, treatment, and prevention. <i>Lancet, The</i> , 2014, 384, 258-271.	6.3	616
7	Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. <i>Lancet HIV,the</i> , 2014, 1, e13-e21.	2.1	542
8	Towards an HIV cure: a global scientific strategy. <i>Nature Reviews Immunology</i> , 2012, 12, 607-614.	10.6	485
9	Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy. <i>PLoS Pathogens</i> , 2014, 10, e1004473.	2.1	437
10	Immune checkpoint blockade in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 91-104.	10.6	407
11	International AIDS Society global scientific strategy: towards an HIV cure 2016. <i>Nature Medicine</i> , 2016, 22, 839-850.	15.2	395
12	CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles. <i>Nature Immunology</i> , 2016, 17, 1187-1196.	7.0	385
13	Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. <i>Hepatology</i> , 2010, 51, 1933-1944.	3.6	366
14	An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients. <i>PLoS Pathogens</i> , 2013, 9, e1003834.	2.1	360
15	CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART. <i>PLoS Pathogens</i> , 2016, 12, e1005761.	2.1	350
16	Measuring Recent Thymic Emigrants in Blood of Normal and HIV-1â€“Infected Individuals before and after Effective Therapy. <i>Journal of Experimental Medicine</i> , 1999, 190, 725-732.	4.2	328
17	Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. <i>Hepatology</i> , 2007, 45, 102-110.	3.6	310
18	The CD16+ Monocyte Subset Is More Permissive to Infection and Preferentially Harbors HIV-1 In Vivo. <i>Journal of Immunology</i> , 2007, 178, 6581-6589.	0.4	302

#	ARTICLE	IF	CITATIONS
19	Isolation and rapid sharing of the 2019 novel coronavirus (<sc>SARS</sc> &CoV&2) from the first patient diagnosed with <sc>COVID</sc> &19 in Australia. Medical Journal of Australia, 2020, 212, 459-462.	0.8	297
20	Getting the &Kill& into &Shock and Kill& Strategies to Eliminate Latent HIV. Cell Host and Microbe, 2018, 23, 14-26.	5.1	285
21	Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society&”Lancet Commission. Lancet, The, 2018, 392, 312-358.	6.3	230
22	CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency. Blood, 2007, 110, 4161-4164.	0.6	220
23	Establishment of HIV-1 latency in resting CD4 ⁺ T cells depends on chemokine-induced changes in the actin cytoskeleton. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16934-16939.	3.3	218
24	Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV,the, 2015, 2, e520-e529.	2.1	213
25	Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed. Hepatology, 2001, 34, 1012-1020.	3.6	201
26	Normal T-Cell Turnover in Sooty Mangabeys Harboring Active Simian Immunodeficiency Virus Infection. Journal of Virology, 2000, 74, 1209-1223.	1.5	185
27	Comparison of HDAC inhibitors in clinical development. Human Vaccines and Immunotherapeutics, 2013, 9, 993-1001.	1.4	173
28	HIV-hepatitis B virus coinfection. Aids, 2017, 31, 2035-2052.	1.0	171
29	Immunopathogenesis of hepatitis B virus infection. Immunology and Cell Biology, 2007, 85, 16-23.	1.0	162
30	Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. Aids, 2006, 20, 863-870.	1.0	159
31	Direct evidence for new T-cell generation by patients after either T-cell&”depleted or unmodified allogeneic hematopoietic stem cell transplantations. Blood, 2002, 100, 2235-2242.	0.6	156
32	PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. Nature Communications, 2019, 10, 814.	5.8	149
33	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Nature Medicine, 2021, 27, 2085-2098.	15.2	146
34	Increased glucose metabolic activity is associated with CD4+ T-cell activation and depletion during chronic HIV infection. Aids, 2014, 28, 297-309.	1.0	141
35	Pharmacy Adherence Measures to Assess Adherence to Antiretroviral Therapy: Review of the Literature and Implications for Treatment Monitoring. Clinical Infectious Diseases, 2011, 52, 493-506.	2.9	139
36	Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. Aids, 2018, 32, 1491-1497.	1.0	136

#	ARTICLE	IF	CITATIONS
37	Restoration of Replication Phenotype of Lamivudine-Resistant Hepatitis B Virus Mutants by Compensatory Changes in the "Fingers" Subdomain of the Viral Polymerase Selected as a Consequence of Mutations in the Overlapping S Gene. <i>Virology</i> , 2002, 299, 88-99.	1.1	133
38	Shocking HIV out of hiding. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 394-401.	1.5	130
39	Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. <i>Aids</i> , 2015, 29, 504-506.	1.0	127
40	A randomized trial of combination hepatitis B therapy in HIV/HBV coinfecting antiretroviral naïve individuals in Thailand. <i>Hepatology</i> , 2008, 48, 1062-1069.	3.6	121
41	Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4+ T cells in thymomas. <i>Blood</i> , 2002, 100, 159-166.	0.6	117
42	HIV and co-infections. <i>Immunological Reviews</i> , 2013, 254, 114-142.	2.8	116
43	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. <i>Cell Reports Medicine</i> , 2021, 2, 100208.	3.3	115
44	HIV cure and eradication: how will we get from the laboratory to effective clinical trials?. <i>Aids</i> , 2011, 25, 885-897.	1.0	113
45	HDAC inhibitors in HIV. <i>Immunology and Cell Biology</i> , 2012, 90, 47-54.	1.0	113
46	Inhibition of Telomerase Activity by Human Immunodeficiency Virus (HIV) Nucleos(t)ide Reverse Transcriptase Inhibitors: A Potential Factor Contributing to HIV-Associated Accelerated Aging. <i>Journal of Infectious Diseases</i> , 2013, 207, 1157-1165.	1.9	113
47	Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy. <i>Nature Communications</i> , 2017, 8, 69.	5.8	111
48	Biological Determinants of Immune Reconstitution in HIV-Infected Patients Receiving Antiretroviral Therapy: The Role of Interleukin 7 and Interleukin 7 Receptor β and Microbial Translocation. <i>Journal of Infectious Diseases</i> , 2010, 202, 1254-1264.	1.9	109
49	Virologically Suppressed HIV Patients Show Activation of NK Cells and Persistent Innate Immune Activation. <i>Journal of Immunology</i> , 2012, 189, 1491-1499.	0.4	109
50	Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. <i>Virology</i> , 2005, 337, 384-398.	1.1	108
51	Exposure to Dideoxynucleosides Is Reflected in Lowered Mitochondrial DNA in Subcutaneous Fat. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 30, 271-277.	0.9	104
52	Both CD31 ⁺ and CD31 ⁺ Naive CD4 ⁺ T Cells Are Persistent HIV Type 1-Infected Reservoirs in Individuals Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2010, 202, 1738-1748.	1.9	102
53	CD4+ T-Cell Deficiency in HIV Patients Responding to Antiretroviral Therapy Is Associated With Increased Expression of Interferon-Stimulated Genes in CD4+ T Cells. <i>Journal of Infectious Diseases</i> , 2011, 204, 1927-1935.	1.9	100
54	Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty. <i>Immunology and Cell Biology</i> , 2003, 81, 487-495.	1.0	99

#	ARTICLE	IF	CITATIONS
55	Barriers and strategies to achieve a cure for HIV. <i>Lancet HIV</i> , 2018, 5, e317-e328.	2.1	99
56	Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. <i>Aids</i> , 2013, 27, 2089-2099.	1.0	98
57	Paediatric HIV infection: the potential for cure. <i>Nature Reviews Immunology</i> , 2016, 16, 259-271.	10.6	97
58	Identification of Lineage Relationships and Novel Markers of Blood and Skin Human Dendritic Cells. <i>Journal of Immunology</i> , 2013, 190, 66-79.	0.4	96
59	Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, 911-919.	1.9	95
60	Functional cure of HIV: the scale of the challenge. <i>Nature Reviews Immunology</i> , 2019, 19, 45-54.	10.6	93
61	HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission. <i>PLoS Pathogens</i> , 2015, 11, e1005000.	2.1	92
62	Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B. <i>Gut</i> , 2015, 64, 1810-1815.	6.1	92
63	Splenectomy Associated Changes in IgM Memory B Cells in an Adult Spleen Registry Cohort. <i>PLoS ONE</i> , 2011, 6, e23164.	1.1	92
64	Differential Expression of CD163 on Monocyte Subsets in Healthy and HIV-1 Infected Individuals. <i>PLoS ONE</i> , 2011, 6, e19968.	1.1	91
65	Ten years of highly active antiretroviral therapy for HIV infection. <i>Medical Journal of Australia</i> , 2007, 186, 146-151.	0.8	85
66	Immunopathogenesis of Hepatic Flare in HIV/Hepatitis B Virus (HBV)-Coinfected Individuals after the Initiation of HBV-Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2009, 199, 974-981.	1.9	83
67	Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. <i>Retrovirology</i> , 2011, 8, 80.	0.9	82
68	Persistent immune activation in chronic HIV infection. <i>Aids</i> , 2013, 27, 1199-1208.	1.0	80
69	HIV-1 Down-Modulates \hat{I}^3 Signaling Chain of Fc \hat{I}^3 R in Human Macrophages: A Possible Mechanism for Inhibition of Phagocytosis. <i>Journal of Immunology</i> , 2002, 168, 2895-2903.	0.4	79
70	Reduced Hepatitis B Virus (HBV)-Specific CD4 + T-Cell Responses in Human Immunodeficiency Virus Type 1-HBV-Coinfected Individuals Receiving HBV-Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2005, 79, 3038-3051.	1.5	76
71	A Systematic Review of T-cell Epitopes in Hepatitis B Virus: Identification, Genotypic Variation and Relevance to Antiviral Therapeutics. <i>Antiviral Therapy</i> , 2008, 13, 161-176.	0.6	75
72	Altering cell death pathways as an approach to cure HIV infection. <i>Cell Death and Disease</i> , 2013, 4, e718-e718.	2.7	73

#	ARTICLE	IF	CITATIONS
73	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. <i>Journal of Infectious Diseases</i> , 2019, 219, 1084-1094.	1.9	73
74	Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw189.	0.4	72
75	Quantification of mitochondrial DNA in peripheral blood mononuclear cells and subcutaneous fat using real-time polymerase chain reaction. <i>Journal of Clinical Virology</i> , 2001, 22, 241-247.	1.6	70
76	HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism. <i>Journal of Virology</i> , 2011, 85, 4330-4342.	1.5	70
77	Patterns and Causes of Suboptimal Response to Tenofovir-Based Therapy in Individuals Coinfected With HIV and Hepatitis B Virus. <i>Clinical Infectious Diseases</i> , 2013, 56, e87-e94.	2.9	69
78	Persistence of integrated HIV DNA in CXCR3+CCR6+ memory CD4+ T cells in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2016, 30, 1511-1520.	1.0	68
79	Chemokine Levels and Chemokine Receptor Expression in the Blood and the Cerebrospinal Fluid of HIV-Infected Patients With Cryptococcal Meningitis and Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome. <i>Journal of Infectious Diseases</i> , 2013, 208, 1604-1612.	1.9	67
80	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. <i>Nature Communications</i> , 2021, 12, 4450.	5.8	67
81	Surface CD4 Is Critical to <i>in Vitro</i> HIV Infection of Human Alveolar Macrophages. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 877-883.	0.5	65
82	HIV-1 DNA and mRNA concentrations are similar in peripheral blood monocytes and alveolar macrophages in HIV-1-infected individuals. <i>Aids</i> , 1998, 12, 719-727.	1.0	65
83	Broad activation of latent HIV-1 <i>in vivo</i> . <i>Nature Communications</i> , 2016, 7, 12731.	5.8	65
84	Myeloid Dendritic Cells Induce HIV-1 Latency in Non-proliferating CD4+ T Cells. <i>PLoS Pathogens</i> , 2013, 9, e1003799.	2.1	63
85	Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells. <i>Aids</i> , 2013, 27, 2853-2862.	1.0	63
86	Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. <i>Biomarkers in Medicine</i> , 2011, 5, 171-186.	0.6	62
87	The search for an HIV cure: tackling latent infection. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 614-621.	4.6	61
88	Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2017, 215, 1684-1694.	1.9	61
89	HIV-1 cell entry and advances in viral entry inhibitor therapy. <i>Journal of Clinical Virology</i> , 2003, 26, 121-132.	1.6	60
90	Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains <i>in vivo</i> . <i>Retrovirology</i> , 2007, 4, 66.	0.9	60

#	ARTICLE	IF	CITATIONS
91	Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 35-42.	1.5	60
92	A Cautionary Tale: Fatal Lactic Acidosis Complicating Nucleoside Analogue and Metformin Therapy. <i>Clinical Infectious Diseases</i> , 2003, 37, 315-316.	2.9	59
93	Associations between surface markers on blood monocytes and carotid atherosclerosis in HIV-positive individuals. <i>Immunology and Cell Biology</i> , 2014, 92, 133-138.	1.0	59
94	HIV integration sites in latently infected cell lines: evidence of ongoing replication. <i>Retrovirology</i> , 2017, 14, 2.	0.9	59
95	Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. <i>Aids</i> , 2003, 17, 1649-1657.	1.0	57
96	Immune Restoration Diseases Reflect Diverse Immunopathological Mechanisms. <i>Clinical Microbiology Reviews</i> , 2009, 22, 651-663.	5.7	57
97	A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. <i>Retrovirology</i> , 2013, 10, 43.	0.9	57
98	Enrichment of gut-derived <i>Fusobacterium</i> is associated with suboptimal immune recovery in HIV-infected individuals. <i>Scientific Reports</i> , 2018, 8, 14277.	1.6	57
99	Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations. <i>Blood</i> , 2002, 100, 2235-2242.	0.6	57
100	Metabolically active CD4+ T cells expressing Glut1 and OX40 preferentially harbor HIV during <i>in vitro</i> infection. <i>FEBS Letters</i> , 2017, 591, 3319-3332.	1.3	56
101	Cytomegalovirus Reactivation Is Associated with Increased Risk of Late-Onset Invasive Fungal Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Study in the Current Era of Viral Load Monitoring. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1961-1967.	2.0	56
102	Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting. <i>Journal of Infectious Diseases</i> , 2020, 222, 1280-1288.	1.9	56
103	Intensification of Antiretroviral Therapy With Raltegravir or Addition of Hyperimmune Bovine Colostrum in HIV-Infected Patients With Suboptimal CD4+ T-Cell Response: A Randomized Controlled Trial. <i>Journal of Infectious Diseases</i> , 2011, 204, 1532-1540.	1.9	54
104	Graves' Disease During Immune Reconstitution After Highly Active Antiretroviral Therapy for HIV Infection: Evidence of Thymic Dysfunction. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 157-162.	0.5	52
105	Human immunodeficiency virus infection and the liver. <i>World Journal of Hepatology</i> , 2012, 4, 91.	0.8	52
106	Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfecting individuals. <i>Aids</i> , 2009, 23, 1707-1715.	1.0	50
107	HIV Reservoirs and Strategies for Eradication. <i>Current HIV/AIDS Reports</i> , 2012, 9, 5-15.	1.1	50
108	<i>In Vivo</i> T Cell-Targeting Nanoparticle Drug Delivery Systems: Considerations for Rational Design. <i>ACS Nano</i> , 2021, 15, 3736-3753.	7.3	50

#	ARTICLE	IF	CITATIONS
109	Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. <i>Science Translational Medicine</i> , 2022, 14, eabl3836.	5.8	50
110	Dynamics of T Cells and TCR Excision Circles Differ After Treatment of Acute and Chronic HIV Infection. <i>Journal of Immunology</i> , 2002, 169, 4657-4666.	0.4	49
111	Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. <i>Antiviral Research</i> , 2002, 55, 381-396.	1.9	49
112	The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. <i>Hepatology</i> , 2007, 46, 1332-1340.	3.6	48
113	Coinfection of Hepatic Cell Lines with Human Immunodeficiency Virus and Hepatitis B Virus Leads to an Increase in Intracellular Hepatitis B Surface Antigen. <i>Journal of Virology</i> , 2010, 84, 5860-5867.	1.5	48
114	Cryptococcosis-IRIS is Associated With Lower Cryptococcus-specific IFN- γ Responses Before Antiretroviral Therapy but Not Higher T-Cell Responses During Therapy. <i>Journal of Infectious Diseases</i> , 2013, 208, 898-906.	1.9	47
115	Immune Monitoring for CMV in Transplantation. <i>Current Infectious Disease Reports</i> , 2018, 20, 4.	1.3	47
116	Between a shock and a hard place: challenges and developments in HIV latency reversal. <i>Current Opinion in Virology</i> , 2019, 38, 1-9.	2.6	47
117	Novel Sensitive Real-Time PCR for Quantification of Bacterial 16S rRNA Genes in Plasma of HIV-Infected Patients as a Marker for Microbial Translocation. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3691-3693.	1.8	46
118	Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells. <i>PLoS Pathogens</i> , 2015, 11, e1005237.	2.1	46
119	The case for an HIV cure and how to get there. <i>Lancet HIV</i> , 2021, 8, e51-e58.	2.1	46
120	Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. <i>Aids</i> , 2011, 25, 197-205.	1.0	44
121	Hepatitis B and Delta Virus Are Prevalent but Often Subclinical Co-Infections among HIV Infected Patients in Guinea-Bissau, West Africa: A Cross-Sectional Study. <i>PLoS ONE</i> , 2014, 9, e99971.	1.1	44
122	Balamuthia mandrillaris brain abscess successfully treated with complete surgical excision and prolonged combination antimicrobial therapy. <i>Journal of Neurosurgery</i> , 2011, 114, 458-462.	0.9	43
123	Changes in Mitochondrial DNA in Peripheral Blood Mononuclear Cells from HIV-Infected Patients with Lipotrophy Randomized to Receive Abacavir. <i>Journal of Infectious Diseases</i> , 2004, 190, 688-692.	1.9	42
124	The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. <i>Aids</i> , 2008, 22, 947-955.	1.0	42
125	Immunopathogenesis: Role of Innate and Adaptive Immune Responses. <i>Seminars in Liver Disease</i> , 2006, 26, 104-115.	1.8	41
126	Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals. <i>PLoS ONE</i> , 2013, 8, e61297.	1.1	41

#	ARTICLE	IF	CITATIONS
127	Finding a cure for HIV: will it ever be achievable?. <i>Journal of the International AIDS Society</i> , 2011, 14, 4-4.	1.2	39
128	Viral Adaptation to Host Immune Responses Occurs in Chronic Hepatitis B Virus (HBV) Infection, and Adaptation Is Greatest in HBV e Antigen-Negative Disease. <i>Journal of Virology</i> , 2012, 86, 1181-1192.	1.5	39
129	Biomarkers of Inflammation and Coagulation Are Associated With Mortality and Hepatitis Flares in Persons Coinfected With HIV and Hepatitis Viruses. <i>Journal of Infectious Diseases</i> , 2013, 207, 1379-1388.	1.9	39
130	Human Immunodeficiency Virus (HIV)â€“Infected CCR6+ Rectal CD4+ T Cells and HIV Persistence On Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 744-755.	1.9	39
131	A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. <i>Antiviral Therapy</i> , 2008, 13, 161-75.	0.6	39
132	The testis and epididymis are productively infected by SIV and SHIV in juvenile macaques during the post-acute stage of infection. <i>Retrovirology</i> , 2007, 4, 7.	0.9	38
133	Virologic Determinants of Success After Structured Treatment Interruptions of Antiretrovirals in Acute HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 140-147.	0.9	38
134	HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry. <i>Retrovirology</i> , 2011, 8, 89.	0.9	38
135	Perceptions of HIV cure research among people living with HIV in Australia. <i>PLoS ONE</i> , 2018, 13, e0202647.	1.1	38
136	Combination Immune Checkpoint Blockade to Reverse HIV Latency. <i>Journal of Immunology</i> , 2020, 204, 1242-1254.	0.4	38
137	Multi-stakeholder consensus on a target product profile for an HIV cure. <i>Lancet HIV</i> , 2021, 8, e42-e50.	2.1	38
138	Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance. <i>Nature Communications</i> , 2021, 12, 4270.	5.8	37
139	Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. <i>Aids</i> , 2007, 21, 1701-1710.	1.0	36
140	Preferential Infection of Dendritic Cells during Human Immunodeficiency Virus Type 1 Infection of Blood Leukocytes. <i>Journal of Virology</i> , 2007, 81, 2297-2306.	1.5	36
141	Diverse effects of interferon alpha on the establishment and reversal of HIV latency. <i>PLoS Pathogens</i> , 2020, 16, e1008151.	2.1	36
142	A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. <i>Annals of Internal Medicine</i> , 2022, 175, 95-100.	2.0	36
143	Effects of HIV-1 infection in vitro on transendothelial migration by monocytes and monocyte-derived macrophages. <i>Journal of Leukocyte Biology</i> , 2009, 85, 1027-1035.	1.5	35
144	Impaired Quality of the Hepatitis B Virus (HBV)-Specific T-Cell Response in Human Immunodeficiency Virus Type 1-HBV Coinfection. <i>Journal of Virology</i> , 2009, 83, 7649-7658.	1.5	35

#	ARTICLE	IF	CITATIONS
145	A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner". <i>Pathogens and Immunity</i> , 2016, 1, 154.	1.4	35
146	Prolonged use of tenofovir in HIV/hepatitis B virus (HBV) coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations. <i>HIV Medicine</i> , 2009, 10, 229-235.	1.0	34
147	The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells. <i>Aids</i> , 2009, 23, 2047-2050.	1.0	34
148	CNS-specific regulatory elements in brain-derived HIV-1 strains affect responses to latency-reversing agents with implications for cure strategies. <i>Molecular Psychiatry</i> , 2016, 21, 574-584.	4.1	34
149	The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. <i>Lancet HIV</i> , 2018, 5, e221-e230.	2.1	34
150	Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. <i>Aids</i> , 2019, 33, 773-791.	1.0	34
151	Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e1973-e1981.	2.9	34
152	Major health impact of accelerated aging in young HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2017, 31, 1393-1403.	1.0	34
153	Clinical Predictors of Immune Reconstitution following Combination Antiretroviral Therapy in Patients from the Australian HIV Observational Database. <i>PLoS ONE</i> , 2011, 6, e20713.	1.1	34
154	Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 328-337.	0.9	32
155	HIV-1 envelope receptor interactions required for macrophage infection and implications for current HIV-1 cure strategies. <i>Journal of Leukocyte Biology</i> , 2013, 95, 71-81.	1.5	31
156	Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. <i>Journal of Clinical Investigation</i> , 2020, 130, 2845-2858.	3.9	31
157	Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 140-47.	0.9	31
158	Thymic Function in Severely Immunodeficient HIV Type 1-Infected Patients Receiving Stable and Effective Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 163-170.	0.5	29
159	Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand. <i>Antiviral Therapy</i> , 2010, 15, 917-922.	0.6	29
160	Targeting antigen to bone marrow stromal cell ² expressed by conventional and plasmacytoid dendritic cells elicits efficient antigen presentation. <i>European Journal of Immunology</i> , 2013, 43, 595-605.	1.6	29
161	Lipopolysaccharide, Immune Activation, and Liver Abnormalities in HIV/Hepatitis B Virus (HBV) Coinfected Individuals Receiving HBV-Active Combination Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2014, 210, 745-751.	1.9	29
162	The role of antigen presenting cells in the induction of HIV-1 latency in resting CD4+ T-cells. <i>Retrovirology</i> , 2015, 12, 76.	0.9	29

#	ARTICLE	IF	CITATIONS
163	The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed. <i>Journal of Virology</i> , 2018, 92, .	1.5	29
164	Population Pharmacokinetics and Pharmacodynamics of Disulfiram on Inducing Latent HIV-1 Transcription in a Phase IIb Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 692-702.	2.3	29
165	Association Between Plasma Antibody Responses and Risk for Cryptococcus-Associated Immune Reconstitution Inflammatory Syndrome. <i>Journal of Infectious Diseases</i> , 2019, 219, 420-428.	1.9	29
166	Multi-site assessment of rapid, point-of-care antigen testing for the diagnosis of SARS-CoV-2 infection in a low-prevalence setting: A validation and implementation study. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 9, 100115.	1.3	29
167	HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing. <i>Virology</i> , 2010, 405, 539-547.	1.1	28
168	The role of naïve T-cells in HIV-1 pathogenesis: An emerging key player. <i>Clinical Immunology</i> , 2011, 141, 253-267.	1.4	28
169	Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells. <i>Journal of NeuroVirology</i> , 2016, 22, 455-463.	1.0	28
170	Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1. <i>Aids</i> , 2018, 32, 2119-2128.	1.0	28
171	Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infection. <i>PLoS Pathogens</i> , 2020, 16, e1008744.	2.1	28
172	HIV inhibits early signal transduction events triggered by CD16 cross-linking on NK cells, which are important for antibody-dependent cellular cytotoxicity. <i>Journal of Leukocyte Biology</i> , 2010, 89, 149-158.	1.5	27
173	Chronic Hepatitis B Infection and Pregnancy. <i>Obstetrical and Gynecological Survey</i> , 2012, 67, 37-44.	0.2	27
174	Experiences and expectations of participants completing an HIV cure focused clinical trial. <i>Aids</i> , 2015, 29, 248-250.	1.0	27
175	The role of SNPs in the β -chain of the IL-7R gene in CD4+ T-cell recovery in HIV-infected African patients receiving suppressive cART. <i>Genes and Immunity</i> , 2012, 13, 83-93.	2.2	26
176	Ex Vivo Response to Histone Deacetylase (HDAC) Inhibitors of the HIV Long Terminal Repeat (LTR) Derived from HIV-Infected Patients on Antiretroviral Therapy. <i>PLoS ONE</i> , 2014, 9, e113341.	1.1	26
177	HIV integration sites and implications for maintenance of the reservoir. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 152-159.	1.5	26
178	Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy. <i>PLoS ONE</i> , 2016, 11, e0160192.	1.1	26
179	Thymic plasmacytoid dendritic cells are susceptible to productive HIV-1 infection and efficiently transfer R5 HIV-1 to thymocytes in vitro. <i>Retrovirology</i> , 2011, 8, 43.	0.9	25
180	Towards a cure for HIV—are we making progress?. <i>Lancet</i> , The, 2014, 384, 209-211.	6.3	25

#	ARTICLE	IF	CITATIONS
181	HIV integration and the establishment of latency in CCL19-treated resting CD4+ T cells require activation of NF- κ B. <i>Retrovirology</i> , 2016, 13, 49.	0.9	25
182	Relationship between CD4 T cell turnover, cellular differentiation and HIV persistence during ART. <i>PLoS Pathogens</i> , 2021, 17, e1009214.	2.1	25
183	Age-dependent changes in T cell homeostasis and SIV load in sooty mangabeys. <i>Journal of Medical Primatology</i> , 2003, 29, 158-165.	0.3	24
184	Immunological and Virological Failure after Antiretroviral Therapy Is Associated with Enhanced Peripheral and Thymic Pathogenicity. <i>Journal of Infectious Diseases</i> , 2003, 187, 1915-1923.	1.9	24
185	Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. <i>Hepatology</i> , 2008, 48, 741-749.	3.6	24
186	Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfecting subjects initiating HBV-active antiretroviral therapy in Thailand. <i>AIDS Research and Therapy</i> , 2012, 9, 6.	0.7	24
187	HIV latency reversing agents act through Tat post translational modifications. <i>Retrovirology</i> , 2018, 15, 36.	0.9	24
188	Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 260-267.	0.5	24
189	The significance and expectations of HIV cure research among people living with HIV in Australia. <i>PLoS ONE</i> , 2020, 15, e0229733.	1.1	24
190	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. <i>EBioMedicine</i> , 2021, 65, 103241.	2.7	24
191	A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. <i>Journal of Virus Eradication</i> , 2020, 6, 100004.	0.3	23
192	Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab239.	0.4	23
193	Comparison of Sequence Analysis and a Novel Discriminatory Real-Time PCR Assay for Detection and Quantification of Lamivudine-Resistant Hepatitis B Virus Strains. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3809-3812.	1.8	22
194	Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfecting individuals: Similar effectiveness of lamivudine, tenofovir, or combination therapy. <i>Hepatology</i> , 2009, 49, 1113-1121.	3.6	22
195	Immunity in young adult survivors of childhood leukemia is similar to the elderly rather than age-matched controls: Role of cytomegalovirus. <i>European Journal of Immunology</i> , 2016, 46, 1715-1726.	1.6	22
196	Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. <i>Journal of Virology</i> , 2017, 91, .	1.5	21
197	PD-1 Expression in HIV-Specific CD8+ T cells Before Antiretroviral Therapy Is Associated With HIV Persistence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 1-6.	0.9	21
198	Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days. <i>PLoS Pathogens</i> , 2016, 12, e1005740.	2.1	21

#	ARTICLE	IF	CITATIONS
199	Relative Significance of Different Pathways of Immune Reconstitution in HIV Type 1 Infection as Estimated by Mathematical Modeling. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 147-159.	0.5	20
200	The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets. <i>Virology</i> , 2013, 442, 51-58.	1.1	20
201	Ethics of ART interruption after stem-cell transplantation. <i>Lancet HIV</i> , 2016, 3, e8-e10.	2.1	20
202	Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection—Lessons for Functional HBV Cure?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, 527-533.	0.9	20
203	Substantial Improvements in Performance Indicators Achieved in a Peripheral Blood Mononuclear Cell Cryopreservation Quality Assurance Program Using Single Donor Samples. <i>Vaccine Journal</i> , 2007, 14, 52-59.	3.2	19
204	Compartmentalization of innate immune responses in the central nervous system during cryptococcal meningitis/HIV coinfection. <i>Aids</i> , 2014, 28, 657-666.	1.0	19
205	Liver Fibrosis Regression Measured by Transient Elastography in Human Immunodeficiency Virus (HIV)-Hepatitis B Virus (HBV)-Coinfected Individuals on Long-Term HBV-Active Combination Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw035.	0.4	19
206	Cancer therapies in HIV cure research. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 96-104.	1.5	19
207	Enhanced Replicative Capacity and Pathogenicity of HIV-1 Isolated From Individuals Infected With Drug-Resistant Virus and Declining CD4+ T-Cell Counts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 140-148.	0.9	18
208	No Increase in Hepatitis B Virus (HBV)-Specific CD8 ⁺ T Cells in Patients with HIV-1-HBV Coinfections following HBV-Active Highly Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2010, 84, 2657-2665.	1.5	18
209	Plasma But Not Cerebrospinal Fluid Interleukin 7 and Interleukin 5 Levels Predict Antiretroviral Therapy Commencement Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome. <i>Clinical Infectious Diseases</i> , 2017, 65, 1551-1559.	2.9	18
210	A gathering storm. <i>Aids</i> , 2019, 33, 1105-1115.	1.0	18
211	CXCR4-Using HIV Strains Predominate in Naive and Central Memory CD4 ⁺ T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained. <i>Journal of Virology</i> , 2020, 94, .	1.5	18
212	The pathogenesis of liver disease in the setting of HIV–hepatitis B virus coinfection. <i>Antiviral Therapy</i> , 2009, 14, 155-164.	0.6	18
213	The Sydney Declaration: a call to scale up research. <i>Lancet</i> , 2007, 370, 7-8.	6.3	17
214	Fatal Acute Varicella–Zoster Virus Hemorrhagic Meningomyelitis with Necrotizing Vasculitis in an HIV-Infected Patient. <i>Clinical Infectious Diseases</i> , 2009, 48, 372-373.	2.9	17
215	Pharmacy and Self-Report Adherence Measures to Predict Virological Outcomes for Patients on Free Antiretroviral Therapy in Tamil Nadu, India. <i>AIDS and Behavior</i> , 2013, 17, 2253-2259.	1.4	17
216	Hepatitis C prevalence among HIV-infected patients in Guinea-Bissau: a descriptive cross-sectional study. <i>International Journal of Infectious Diseases</i> , 2014, 28, 35-40.	1.5	17

#	ARTICLE	IF	CITATIONS
217	Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4+T Cells. <i>Journal of Immunology</i> , 2018, 201, 1468-1477.	0.4	17
218	Hepatitis virus immune restoration disease of the liver. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 446-452.	1.5	16
219	HIV Infection and TLR Signalling in the Liver. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-8.	0.7	16
220	A new way of measuring apoptosis by absolute quantitation of inter-nucleosomally fragmented genomic DNA. <i>Nucleic Acids Research</i> , 2012, 40, e113-e113.	6.5	16
221	Circulating Heat Shock Protein 60 Levels Are Elevated in HIV Patients and Are Reduced by Anti-Retroviral Therapy. <i>PLoS ONE</i> , 2012, 7, e45291.	1.1	16
222	Is specific HIV eradication from the brain possible or needed?. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 403-409.	1.4	16
223	The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. <i>Aids</i> , 2021, 35, 1631-1636.	1.0	16
224	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. <i>Journal of Immunology</i> , 2022, 208, 54-62.	0.4	16
225	Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. <i>Aids</i> , 2016, 30, 1597-1606.	1.0	15
226	Decreased NK Cell FcR γ in HIV-1 Infected Individuals Receiving Combination Antiretroviral Therapy: a Cross Sectional Study. <i>PLoS ONE</i> , 2010, 5, e9643.	1.1	15
227	Immune checkpoint blockade in HIV. <i>EBioMedicine</i> , 2022, 76, 103840.	2.7	15
228	Human cytomegalovirus (CMV)-specific CD8+ T cell responses are reduced in HIV-infected individuals with a history of CMV disease despite CD4+ T cell recovery. <i>Clinical Immunology</i> , 2007, 124, 200-206.	1.4	14
229	The "network" of women when considering and using interventions to reduce mother-to-child transmission (MTCT) of HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2009, 21, 1230-1237.	0.6	14
230	HIV persistence: Chemokines and their signalling pathways. <i>Cytokine and Growth Factor Reviews</i> , 2012, 23, 151-157.	3.2	14
231	Comparison of Etests and Vitek 2 \hat{A} to broth microdilution for the susceptibility testing of <i>Cryptococcus neoformans</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 80, 294-298.	0.8	14
232	Kick and kill for HIV latency. <i>Lancet, The</i> , 2020, 395, 844-846.	6.3	14
233	The end of HIV: Still a very long way to go, but progress continues. <i>PLoS Medicine</i> , 2017, 14, e1002466.	3.9	14
234	No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET Trial. <i>PLoS ONE</i> , 2014, 9, e109718.	1.1	13

#	ARTICLE	IF	CITATIONS
235	Polymorphisms in the CD14 and TLR4 genes independently predict CD4+ T-cell recovery in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2016, 30, 2159-2168.	1.0	13
236	Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa. <i>Journal of Infectious Diseases</i> , 2016, 214, 73-79.	1.9	13
237	Ethics and hepatitis B cure research. <i>Gut</i> , 2017, 66, 389-392.	6.1	13
238	Post-treatment control in an adult with perinatally acquired HIV following cessation of antiretroviral therapy. <i>Aids</i> , 2017, 31, 1344-1346.	1.0	13
239	Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2017, 8, 1506.	2.2	13
240	Tat IRES modulator of tat mRNA (TIM-TAM): a conserved RNA structure that controls Tat expression and acts as a switch for HIV productive and latent infection. <i>Nucleic Acids Research</i> , 2020, 48, 2643-2660.	6.5	13
241	Comparison of Real-Time PCR Assays for Monitoring Serum Hepatitis B Virus DNA Levels during Antiviral Therapy. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2983-2987.	1.8	12
242	Antibody and B-cell responses may control circulating lipopolysaccharide in patients with HIV infection. <i>Aids</i> , 2011, 25, 1379-1383.	1.0	12
243	Short Communication: CD4 T Cell Declines Occurring During Suppressive Antiretroviral Therapy Reflect Continued Production of Casp8p41. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 476-479.	0.5	12
244	HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV. <i>BMC Infectious Diseases</i> , 2016, 16, 114.	1.3	12
245	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. <i>EBioMedicine</i> , 2021, 65, 103252.	2.7	12
246	Incidence of putative HIV superinfection and sexual practices among HIV-infected men who have sex with men. <i>Sexual Health</i> , 2008, 5, 61.	0.4	12
247	The role of bronchoscopy in the diagnosis and treatment of pulmonary disease in HIV-infected patients. <i>Australian and New Zealand Journal of Medicine</i> , 1995, 25, 133-139.	0.5	11
248	Antenatal screening practice for infectious diseases by general practitioners in Australia. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2009, 49, 39-44.	0.4	11
249	A novel, rapid method to detect infectious HIV-1 from plasma of persons infected with HIV-1. <i>Journal of Virological Methods</i> , 2010, 165, 90-96.	1.0	11
250	HIV replication is associated with increased severity of liver biopsy changes in HIV-HBV and HIV-HCV co-infection. <i>Journal of Medical Virology</i> , 2012, 84, 993-1001.	2.5	11
251	CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2019, 93, .	1.5	11
252	Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5148-5175.	2.9	11

#	ARTICLE	IF	CITATIONS
253	Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa115.	0.4	11
254	In vitro replication phenotype of a novel (H1N) hepatitis B virus variant associated with HIV coinfection. <i>Journal of Medical Virology</i> , 2012, 84, 1166-1176.	2.5	10
255	Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. <i>Aids</i> , 2017, 31, 1839-1845.	1.0	10
256	Modeling of Antilateness Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?. <i>Journal of Virology</i> , 2017, 91, .	1.5	10
257	Relationship of Human Immunodeficiency Virus Viral Load in Cerebrospinal Fluid and Plasma in Patients Co-infected With Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx032.	0.4	10
258	Factors Associated with Elevated ALT in an International HIV/HBV Co-Infected Cohort on Long-Term HAART. <i>PLoS ONE</i> , 2011, 6, e26482.	1.1	10
259	A Randomized Controlled Trial of Lisinopril to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Individuals. <i>Pathogens and Immunity</i> , 2017, 2, 310.	1.4	10
260	Immune recovery uveitis in an HIV-negative individual. <i>Clinical and Experimental Ophthalmology</i> , 2007, 35, 189-190.	1.3	9
261	Human thymic dendritic cells: Regulators of T cell development in health and HIV-1 infection. <i>Clinical Immunology</i> , 2008, 126, 1-12.	1.4	9
262	Early Events of HIV-1 Infection: Can Signaling be the Next Therapeutic Target?. <i>Journal of NeuroImmune Pharmacology</i> , 2011, 6, 269-283.	2.1	9
263	A cure for HIV: where we've been, and where we're headed. <i>Lancet, The</i> , 2013, 381, 2057-2058.	6.3	9
264	The CD14 C-260T single nucleotide polymorphism (SNP) modulates monocyte/macrophage activation in treated HIV-infected individuals. <i>Journal of Translational Medicine</i> , 2015, 13, 30.	1.8	9
265	No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. <i>Aids</i> , 2017, 31, 1137-1141.	1.0	9
266	2018 international meeting of the Global Virus Network. <i>Antiviral Research</i> , 2019, 163, 140-148.	1.9	9
267	Limitations of dual-fluorescent HIV reporter viruses in a model of pre-activation latency. <i>Journal of the International AIDS Society</i> , 2019, 22, e25425.	1.2	9
268	Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies. <i>AIDS Research and Therapy</i> , 2020, 17, 65.	0.7	9
269	Molecular Gymnastics: Mechanisms of HIV-1 Resistance to CCR5 Antagonists and Impact on Virus Phenotypes. <i>Current Topics in Medicinal Chemistry</i> , 2015, 16, 1091-1106.	1.0	9
270	A Phase I Study of the Pharmacokinetics and Safety of Passive Immunotherapy with Caprine Anti-HIV Antibodies, PEHRG214, in HIV-1-Infected Individuals. <i>HIV Clinical Trials</i> , 2004, 5, 91-98.	2.0	8

#	ARTICLE	IF	CITATIONS
271	Early experience with antimicrobial stewardship ward rounds at a tertiary referral hospital. <i>Medical Journal of Australia</i> , 2012, 196, 34-35.	0.8	8
272	Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 1220-1235.	0.5	8
273	Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome Is Associated With Dysregulation of IL-7/IL-7 Receptor Signaling Pathway in T Cells and Monocyte Activation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 596-604.	0.9	8
274	HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro. <i>Aids</i> , 2019, 33, 199-209.	1.0	8
275	Leveraging the advances in HIV for COVID-19. <i>Lancet, The</i> , 2020, 396, 943-944.	6.3	8
276	Severe hepatitis and prolonged hepatitis B virus-specific CD8 T-cell response after selection of hepatitis B virus YMDD variant in an HIV/hepatitis B virus-co-infected patient. <i>Aids</i> , 2004, 18, 1734-1737.	1.0	7
277	Future directions in the treatment of HIV+HBV coinfection. <i>HIV Therapy</i> , 2009, 3, 405-415.	0.6	7
278	Preliminary assessment of <i>Treponema pallidum</i> -specific IgM antibody detection and a new rapid point-of-care assay for the diagnosis of syphilis in human immunodeficiency virus-1-infected patients. <i>International Journal of STD and AIDS</i> , 2010, 21, 758-764.	0.5	7
279	CD4+ T cell signatures in HIV infection. <i>Nature Immunology</i> , 2019, 20, 948-950.	7.0	7
280	The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency. <i>Frontiers in Genetics</i> , 2021, 12, 680725.	1.1	7
281	Neurotoxicity with high-dose disulfiram and vorinostat used for HIV latency reversal. <i>Aids</i> , 2022, 36, 75-82.	1.0	7
282	Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In Vitro. <i>PLoS ONE</i> , 2016, 11, e0158778.	1.1	7
283	Cell-Associated Human Immunodeficiency Virus (HIV) Ribonucleic Acid Has a Circadian Cycle in Males With HIV on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2022, 225, 1721-1730.	1.9	7
284	What are the barriers to offering HIV testing in an antenatal setting? A national study of obstetricians. <i>Aids</i> , 2007, 21, 1601-1606.	1.0	6
285	Extremely prolonged HIV seroconversion associated with an MHC haplotype carrying disease susceptibility genes for antibody deficiency disorders. <i>Clinical Immunology</i> , 2010, 137, 199-208.	1.4	6
286	HIV and aging: an overview of an emerging issue. <i>Sexual Health</i> , 2011, 8, 449.	0.4	6
287	Decline in Serum 25 Hydroxyvitamin D Levels in HIV+Hbv-Coinfected Patients after Long-Term Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2014, 19, 41-49.	0.6	6
288	Sexual transmission of HIV and the law: an Australian medical consensus statement. <i>Medical Journal of Australia</i> , 2016, 205, 409-412.	0.8	6

#	ARTICLE	IF	CITATIONS
289	Quantifying Adaptive and Innate Immune Responses in HIV-Infected Participants Using a Novel High Throughput Assay. PLoS ONE, 2016, 11, e0166549.	1.1	6
290	Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients. International Journal of Clinical Pharmacology and Therapeutics, 2015, 53, 947-954.	0.3	6
291	Finding a Cure for HIV: Much Work to Do. Annals of Internal Medicine, 2014, 161, 368.	2.0	5
292	Australian health professionals' statement on climate change and health. Lancet, The, 2018, 392, 2169-2170.	6.3	5
293	TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection. Journal of Immunology, 2019, 203, 718-724.	0.4	5
294	Statistical analysis of single-copy assays when some observations are zero. Journal of Virus Eradication, 2019, 5, 167-173.	0.3	5
295	Tesamorelin, liver fat, and NAFLD in the setting of HIV. Lancet HIV,the, 2019, 6, e808-e809.	2.1	5
296	Pneumocystis carinii pneumonia after cessation of secondary prophylaxis in a patient on highly active antiretroviral therapy with a CD4 cell count greater than 200/mm ³ . Aids, 2001, 15, 1912-1913.	1.0	5
297	Statistical analysis of single-copy assays when some observations are zero. Journal of Virus Eradication, 2019, 5, 167-173.	0.3	5
298	CXCL-10, IL-12 and IL-21 are not immunological predictors of HBeAg seroconversion in HIV-1+HBV coinfection following HBV-active antiretroviral therapy (ART). Antiviral Therapy, 2014, 19, 429-433.	0.6	4
299	Genetic polymorphisms in the CD14 gene are associated with monocyte activation and carotid intima-media thickness in HIV-infected patients on antiretroviral therapy. Medicine (United States), 2016, 95, e4477.	0.4	4
300	Voices of biotech. Nature Biotechnology, 2016, 34, 270-275.	9.4	4
301	HIV cure research: print and online media reporting in Australia. Journal of Virus Eradication, 2017, 3, 229-235.	0.3	4
302	Individuals with HIV-1 Subtype C Infection and Cryptococcal Meningitis Exhibit Viral Genetic Intermixing of HIV-1 Between Plasma and Cerebrospinal Fluid and a High Prevalence of CXCR4-Using Variants. AIDS Research and Human Retroviruses, 2018, 34, 607-620.	0.5	4
303	A cure for HIV: how would we know?. Lancet HIV,the, 2020, 7, e304-e306.	2.1	4
304	Entry of HIV in Primary Human Resting CD4+ T Cells Pretreated with the Chemokine CCL19. AIDS Research and Human Retroviruses, 2014, 30, 207-208.	0.5	3
305	Targets for intervention to improve virological outcomes for patients receiving free antiretroviral therapy in Tamil Nadu, India. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2014, 26, 559-566.	0.6	3
306	Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of <i>In Vitro</i> versus <i>In Vivo</i> Models. Journal of Virology, 2019, 93, .	1.5	3

#	ARTICLE	IF	CITATIONS
307	Circulating BAFF and CXCL10 levels predict response to pegylated interferon in patients with HBeAg-positive chronic hepatitis B. <i>Asian Pacific Journal of Allergy and Immunology</i> , 2021, 39, 129-135.	0.2	3
308	Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 855290.	1.8	3
309	Highly reproducible transient transfections for the study of hepatitis B virus replication based on an internal GFP reporter system. <i>Journal of Virological Methods</i> , 2004, 121, 65-72.	1.0	2
310	Sexually transmissible infection and HIV management among men who have sex with men with and without HIV: survey of medical practitioners who are members of the Australasian Society for HIV Medicine. <i>Sexual Health</i> , 2008, 5, 155.	0.4	2
311	Differential dynamics of donor DC and non-DC peripheral blood mononuclear cell microchimerism in lung transplantation. <i>Clinical Immunology</i> , 2009, 133, 179-183.	1.4	2
312	Is Australia prepared for the next pandemic?. <i>Medical Journal of Australia</i> , 2017, 206, 284-286.	0.8	2
313	Towards a cure for human immunodeficiency virus. <i>Internal Medicine Journal</i> , 2018, 48, 12-15.	0.5	2
314	Longitudinal analysis of subtype C envelope tropism for memory CD4+ T cell subsets over the first 3 years of untreated HIV-1 infection. <i>Retrovirology</i> , 2020, 17, 24.	0.9	2
315	Optimization of 5-substituted thiazolyl ureas and 6-substituted imidazopyridines as potential HIV-1 latency reversing agents. <i>European Journal of Medicinal Chemistry</i> , 2020, 195, 112254.	2.6	2
316	Altered Immune Reconstitution in Allogeneic Stem Cell Transplant Recipients With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2021, 72, 1141-1146.	2.9	2
317	HIV cure research: print and online media reporting in Australia. <i>Journal of Virus Eradication</i> , 2017, 3, 229-235.	0.3	2
318	Multiparameter immunohistochemistry analysis of HIV DNA, RNA and immune checkpoints in lymph node tissue. <i>Journal of Immunological Methods</i> , 2021, , 113198.	0.6	2
319	Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design. <i>Journal of Infectious Diseases</i> , 2022, 226, 236-245.	1.9	2
320	Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19. <i>Journal of the International AIDS Society</i> , 2022, 25, e25882.	1.2	2
321	Phase 1 Single Dose Studies to Optimize the Pharmacokinetics of DG17, a Novel HIV-Protease Inhibitor Pro-Drug, Using Sodium Bicarbonate and Ritonavir. <i>Current HIV Research</i> , 2008, 6, 272-275.	0.2	1
322	Editorial: HIV and lipopolysaccharide: double trouble in the liver. <i>Journal of Leukocyte Biology</i> , 2017, 101, 1077-1079.	1.5	1
323	Outcomes following detection of low level plasma HIV RNA in HIV-infected patients previously virologically suppressed on antiretroviral therapy: a retrospective observational study. <i>Sexual Health</i> , 2017, 14, 238.	0.4	1
324	Hepatitis B Infection in People Living With Human Immunodeficiency Virus: A Global Challenge Needing More Research. <i>Clinical Infectious Diseases</i> , 2020, 71, 2807-2809.	2.9	1

#	ARTICLE	IF	CITATIONS
325	Interrupting antiretroviral therapy in HIV cure trials during COVID-19: Adaptation to low transmission settings. <i>Journal of Virus Eradication</i> , 2021, 7, 100032.	0.3	1
326	HIV persistence in the CNS: the final frontier for a cure?. <i>Journal of Virus Eradication</i> , 2016, 2, 242.	0.3	1
327	HIV research in Australia: linking basic research findings with clinical and public health outcomes. <i>Retrovirology</i> , 2006, 3, 86.	0.9	0
328	Variable uptake of recommended interventions to reduce mother-to-child transmission of HIV in Australia, 1982-2005. <i>Medical Journal of Australia</i> , 2009, 190, 220-221.	0.8	0
329	Australasian HIV/AIDS Conference 2009. <i>HIV Therapy</i> , 2010, 4, 9-11.	0.6	0
330	Ebola and HIV: managing febrile times. <i>Lancet HIV</i> , 2014, 1, e101-e102.	2.1	0
331	Immunopathogenesis of HIV Coinfections. , 2014, , 1-15.		0
332	Combination treatment prevents HIV re-emergence in monkeys. <i>Nature</i> , 2018, 563, 333-335.	13.7	0
333	Reducing the gap between the diagnosis and treatment of HIV infection. <i>Medical Journal of Australia</i> , 2019, 210, 261-262.	0.8	0
334	Editorial. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 151-156.	1.5	0
335	Toll-like Receptor 7 Agonists in People Living With HIV: Implications for Immunotherapeutic Strategies for an HIV Cure. <i>Clinical Infectious Diseases</i> , 2021, 72, e825-e827.	2.9	0
336	Challenges, progress and strategies in the search for a cure for HIV. <i>Microbiology Australia</i> , 2014, 35, 72.	0.1	0
337	Immunopathogenesis of HIV Coinfections. , 2018, , 1083-1096.		0
338	Developing research priorities for Australia's response to infectious disease emergencies. <i>Communicable Diseases Intelligence</i> , 2017, 41, E1-E3.	0.5	0
339	Factors associated with weak positive SARS-CoV-2 diagnosis by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR). <i>Pathology</i> , 2022, , .	0.3	0